Logo do repositório
 
A carregar...
Logótipo do projeto
Projeto de investigação

UNREAD - RadiUm-223 iN metastatic pRostatE cAncer: searching the keys beyond clinical eviDence

Autores

Publicações

Cold atmospheric plasma, a novel approach against bladder cancer, with higher sensitivity for the high-grade cell line
Publication . Tavares-da-Silva, Edgar; Pereira, Eurico; Pires, Ana S.; Neves, Ana R.; Braz-Guilherme, Catarina; Marques, Inês A.; Abrantes, Ana M; Gonçalves, Ana C.; Caramelo, Francisco; Silva-Teixeira, Rafael; Mendes, Fernando; Figueiredo, Arnaldo; Botelho, Maria Filomena
Antitumor therapies based on Cold Atmospheric Plasma (CAP) are an emerging medical field. In this work, we evaluated CAP effects on bladder cancer. Two bladder cancer cell lines were used, HT-1376 (stage III) and TCCSUP (stage IV). Cell proliferation assays were performed evaluating metabolic activity (MTT assay) and protein content (SRB assay). Cell viability, cell cycle, and mitochondrial membrane potential (Δψm) were assessed using flow cytometry. Reactive oxygen and nitrogen species (RONS) and reduced glutathione (GSH) were evaluated by fluorescence. The assays were carried out with different CAP exposure times. For both cell lines, we obtained a significant reduction in metabolic activity and protein content. There was a decrease in cell viability, as well as a cell cycle arrest in S phase. The Δψm was significantly reduced. There was an increase in superoxide and nitric oxide and a decrease in peroxide contents, while GSH content did not change. These results were dependent on the exposure time, with small differences for both cell lines, but overall, they were more pronounced in the TCCSUP cell line. CAP showed to have a promising antitumor effect on bladder cancer, with higher sensitivity for the high-grade cell line.

Unidades organizacionais

Descrição

Palavras-chave

Contribuidores

Financiadores

Entidade financiadora

Fundação para a Ciência e a Tecnologia

Programa de financiamento

POR_CENTRO

Número da atribuição

SFRH/BD/136973/2018

ID